Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Jeff Chan who wrote (1717)	5/2/1999 8:41:00 AM
From: Tom Drolet	Read Replies (1) \| Respond to of 14101

Jeff: Small Dow Jones Newswire article on the recent Q financials-- nothing new--just fyi. April 26, 1999 Dow Jones Newswires Dimethaid Research 9 Mos Losses C$0.31/Shr Vs C$0.17 Dow Jones Newswires Dimethaid Research Inc. - Toronto 9 months Feb. 28: All figures in Canadian dollars 1999 1998 Revenues C$921,023 C$937,286 Net income (11,624,379) (6,203,223) Shr ern (basic) Net income (.31) (.17) Figures in parentheses are losses. The company said research and development spending increased by about C$4.9 million in the nine months versus a year earlier. It said C$4.4 million of the increase was for Oxo Chemie's Phase III clinical trial of WF10 for people with late-stage HIV disease, and the remainder was due to costs associated with regulatory approval for Pennsaid lotion and proposed additional studies of transdermal technology. Dimethaid Research Inc. (T.DMX) is a pharmaceutical company involved in the development of therapeutic solutions that minimize the unwanted effects of drug therapy on the body. -------------------------------------------------------------------------------- Briefing Book for: T.DMX